Onco-miR-24 regulates cell growth and apoptosis by targeting BCL2L11 in gastric cancer by Haiyang Zhang et al.
RESEARCH ARTICLE
Onco-miR-24 regulates cell growth and
apoptosis by targeting BCL2L11 in gastric
cancer
Haiyang Zhang1, Jingjing Duan1, Yanjun Qu1, Ting Deng1, Rui Liu1, Le Zhang1, Ming Bai1, Jialu Li2,
Tao Ning1, Shaohua Ge1, Xia Wang1, Zhenzhen Wang3, Qian Fan1, Hongli Li1, Guoguang Ying1,
Dingzhi Huang1&, Yi Ba1&
1 Tianjin Medical University Cancer Institute and Hospital, Key Laboratory of Cancer Prevention and Therapy, National Clinical
Research Center for Cancer, Tianjin 300060, China
2 Department of Gastroenterology, Tianjin First Center Hospital, Tianjin 300192, China
3 Changchun GeneScience Pharmaceuticals Co., Ltd, Changchun 130012, China
& Correspondence: dingzhih72@163.com (Dingzhi Huang), bayi@tjmuch.com (Y. Ba)
Received September 30, 2015 Accepted November 19, 2015
ABSTRACT
Gastric cancer is one of the most common malignancies
worldwide; however, the molecular mechanism in
tumorigenesis still needs exploration. BCL2L11 belongs
to the BCL-2 family, and acts as a central regulator of the
intrinsic apoptotic cascade and mediates cell apoptosis.
Although miRNAs have been reported to be involved in
each stage of cancer development, the role of miR-24 in
GC has not been reported yet. In the present study, miR-
24 was found to be up-regulated while the expression of
BCL2L11 was inhibited in tumor tissues of GC. Studies
from both in vitro and in vivo shown that miR-24 regu-
lates BCL2L11 expression by directly binding with 3′UTR
of mRNA, thus promoting cell growth, migration while
inhibiting cell apoptosis. Therefore, miR-24 is a novel
onco-miRNA that can be potential drug targets for future
clinical use.
KEYWORDS gastric cancer, BCL2L11, miR-24,
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INTRODUCTION
Gastric cancer (GC) is one of the leading causes of cancer-
related deaths all over the world (Fujita, 2009; Hartgrink et al.,
2009). The conventional therapies for gastric cancer, such as
chemotherapy and radiation, often lead to nonspeciﬁcally
mass cell killing and side effects. Targetedmedicine based on
cancer gene therapy is a promising strategy for the treatment
of gastric cancer (Hohenberger and Gretschel, 2003; Xiong
et al., 2003). However, the number of effective targeted drugs
for GC treatment is relatively less than that in other cancers.
Studies on novel pathways of GC tumorigenesis provide
candidates for drug target.
BCL2L11 is a member of BCL-2 family and is located in the
outer membrane of mitochondria, where this protein acts as an
important regulator that mediates excitotoxic apoptosis, apop-
tosis inducing factor translocation and mitochondrial depolar-
ization (Concannon et al., 2010; Kilbride et al., 2010). Recent
studies showed that BCL2L11 is a dual-agent that regulates
autophagy in drug resistance (Dai and Grant, 2015), and
BCL2L11 is also involved in neural apoptosis in methylmalonic
academia (Li et al., 2014). The anti-apoptotic BCL2 members
have multiple domains; while the pro-apoptotic members of
BCL2 family, including BCL2L11, are BH3-domain-only pro-
teins (Mansha et al., 2013; Frank et al., 2015; Huang et al.,
2015). Although the roleofBCL2L11hasbeen reported in these
biological processes, the information that BCL2L11 regulates
cell growth and apoptosis in cancer, especially in gastroin-
testinal tumors, remains largely unknown.
MicroRNAs (miRNAs) are a novel class of small non-
coding RNAs (∼22 bp) that are believed to regulate gene
expression by directly binding with 3′UTR of target mRNAs,
causing translational inhibition or mRNA degradation
(Ambros, 2004; Bartel, 2004). MiRNAs are usually highly-
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conserved between species, and are regarded as distinct
post-transcriptional regulators that are involved in most of
the physiological and pathological processes, including cell
differentiation, cell proliferation, the immune response,
metabolism, aging process, tumorigenesis and drug resis-
tance (Lim et al., 2005; Zhu et al., 2013; Zhang et al., 2015).
Recent years, serum miRNAs are treated as a novel bio-
marker for the diagnosis and prognosis of various cancers
(Liu et al., 2011; Liu et al., 2012; Ge et al., 2013; Luo et al.,
2013; Wang et al., 2015). Recent studies by our group and
others show that miRNAs can be secreted into the extra-
cellular environment through microvesicles (MVs) and func-
tion as secretory signaling molecules that inﬂuence the
recipient cell phenotypes (Zhang et al., 2010; Li et al., 2013;
Li et al., 2015).
The expression of miR-24 has been found to be dys-
regulated in several cancers (Lin et al., 2010; Qin et al.,
2010; Naito et al., 2015; Organista-Nava et al., 2015; Zhao
et al., 2015). Up-regulation of miR-24 in non-small cell lung
cancer was found to promote cell proliferation (Zhao et al.,
2015). It has been reported that miR-24 is also signiﬁcantly
up-regulated in gastric cancer (Volinia et al., 2006). How-
ever, the molecular mechanism that miR-24 regulate
tumorigenesis in GC remains largely unknown. In the pre-
sent study, we showed that miR-24 is up-regulated, while
BCL2L11 expression is signiﬁcantly suppressed in GC tis-
sues. The subsequent luciferase assay showed that
BCL2L11 is a direct target of miR-24; overexpression of
miR-24 in GC cells leads to the inhibition of BCL2L11, thus
promoting cell proliferation, migration while reducing cell
apoptosis. In vivo experiments demonstrated that high level
of miR-24 clearly accelerates while BCL2L11 overexpres-
sion strongly inhibits tumor growth. Therefore, our data
illustrated a novel pathway comprising miR-24 and
BCL2L11 in GC, which is a potential target for future clinical
use.
RESULTS
BCL2L11 is down-regulated in gastric cancer
Although BCL2L11 is well known to mediate cell apoptosis
(Hagenbuchner et al., 2012; Luo and Rubinsztein, 2013;
Dai and Grant, 2015), its expression pattern and the bio-
logical role in cancer have not been detailedly described
yet. In this study, we ﬁrst compared the mRNA levels and
protein levels in gastric cancer tissues and the paired para-
carcinoma tissues. The expression of BCL2L11 protein
showed clear decrease in GC, which is reduced by nearly
70% of that in para-carcinoma tissues (Fig. 1A and 1B);
however, its mRNA levels did not differ signiﬁcantly
between the cancer and noncancerous tissues (Fig. 1C).
The disparity between mRNA and protein suggested that
BCL2L11 expression mainly depends on post-transcrip-
tional regulators.
Identiﬁcation of miR-24 as a potential upstream
regulator of BCL2L11
One of the important modes of post-transcriptional regulation
is miRNA-mediated repression of mRNA transcripts. By
using bioinformatics tools, we found that miR-24 can directly
target the 3′UTR of BCL2L11 mRNA (Fig. 1D). As is shown
in Fig. 1E, miR-24 binds with BCL2L11 mRNA by comple-
mentary base pairing of two target regions.
It has been reported that miR-24 is signiﬁcantly up-regu-
lated in GC (Volinia et al., 2006), and is even higher after
high-dose expose to radiation (Naito et al., 2015). We here
valued the expression pattern of miR-24 in 6 pairs of tumor
and cancer adjacent tissues. As is expected, miR-24
showed obvious increase in all the tumor tissues (Fig. 1F).
Therefore, miR-24 is most likely to be the important regulator
of BCL2L11 in gastric cancer cells.
Validation of BCL2L11 as a direct target of miR-24
The levels of miR-24 and BCL2L11 showed inverse corre-
lation in GC, and the prediction by bioinformatics suggested
that BCL2L11 is a potential target of miR-24; however, the
direct evidence of the interaction between miR-24 and
BCL2L11 given by luciferase assay is still needed. The rel-
ative luciferase activity was signiﬁcantly inhibited by the co-
transfection of miR-24 mimics and the luciferase reporters
containing the predicted target regions of BCL2L11 mRNA
(Fig. 2B and 2C); while the inhibition was lost when the
binding sites in 3′UTR were mutated (Fig. 2B and 2C). The
luciferase signal showed relative increase when miR-24
inhibitors were used instead (Fig. 2B and 2C).
The expressions of BCL2L11 protein and mRNA were
also determined respectively after the overexpression or
knockdown of miR-24 in SGC7901 cells. Relative levels of
miR-24 in SGC7901 cells were also detected using qRT-
PCR analysis following transfection of mimics or inhibitors
(Fig. 1A). As is shown in Fig. 2D and 2E, the overexpression
of miR-24 by transfection of mimics leads to the clear sup-
pression of BCL2L11 protein, but not BCL2L11 mRNA. While
the transfection of miR-24 inhibitors enhances the expres-
sion of BCL2L11 in SGC7901 cells (Fig. 2D and 2E).
Meanwhile, BCL2L11 mRNA was not changed with the
transfection of mimics or inhibitors (Fig. 2F).
These data demonstrated that miR-24 is an important
regulator of BCL2L11 in GC cells, and miR-24 regulates
BCL2L11 expression by directly targeting the 3′UTR of
BCL2L11 mRNA.
MiR-24 regulates proliferation, migration, apoptosis
of SGC7901 cells
MiR-24 is also found to be obviously up-regulated in gastric
cancer cell lines, SGC7901 and BGC823, compared with
normal gastric cell line (GES-1) (Tchernitsa et al., 2010;
Tsukamoto et al., 2010). In the present study, we assessed
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cell growth, cell metastasis and cell apoptosis in SGC7901
cells transfected with miR-24 mimics or inhibitors.
CCK8 kit was used to measure the growth rate of
SGC7901 cells. As is shown in Fig. 3A, high levels of miR-24
result in a clear increase in cell growth rate, while the inhi-
bition of miR-24 leads to the signiﬁcant suppression of cell
proliferation (Fig. 3B).
The miR-24-BCL2L11 mediated cell apoptosis was
assessed using cell ﬂow assays. SGC7901 cells were
transfected with miR-24 mimics and inhibitors, and fresh
FBS-free RPMI-1640 medium was added to promote cell
apoptosis. The remove of FBS caused a sharp increase of
cell apoptosis compared with control; overexpression of
miR-24 reduced the ratio of cell apoptosis, while transfection
of miR-24 inhibitor further promoted cell apoptosis (Fig. 3C
and 3D).
Effects of miR-24 on cell migration were valued by tran-
swell assay and scrapping method. SGC7901 cells
transfected with miR-24 mimics showed a higher ratio in
migration (Fig. 3E–G). However, cell migration was strongly
inhibited when cells are transfected with miR-24 inhibitors
(Fig. 3E–G).
These results based on in vitro experiments demon-
strated that miR-24 is an onco-miRNA in gastric cancer, and
plays a key role in the biological processes in cancer cells.
Overexpression of BCL2L11 partly reduced
miR-24-induced GC cell growth
To give more evidence that miR-24 promotes tumorigenesis
in gastric cancer, we used miR-24 mimics and lenti-virus
particles to overexpress miR-24 and BCL2L11 in SGC7901
cells simultaneously. As is shown in Fig. 4A and 4B, co-
transfection of miR-24 mimics and BCL2L11 lenti-virus par-
ticles partly rescued BCL2L11 expression compared with the




















































Target 1: Position 664–671 of BCL2L11 3′ UTR ΔG = -24.5 kcal/mol 
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Figure 1. Inverse correlation between BCL2L11 and miR-24 in human GC tissues. (A) Western blot analysis of BCL2L11
expression in GC cancer tissues and the paired para-carcinoma tissues (n = 6). (B) Quantitative analysis of (A). (C) Relative levels of
BCL2L11 mRNA levels in GC tissues (n = 6). (D and E) The predicted binding sites of miR-24 in the mRNA of BCL2L11 (D) and the
base-pairing interaction between miR-24 and BCL2L11 mRNA (E). (F) Relative levels of miR-24 in GC tissues and para-carcinoma
tissues (n = 6). ** indicates P < 0.01.
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overexpression of BCL2L11 in SGC7901 cells partly
decreased miR-24-induced cell proliferation (Fig. 4C) and
migration (Fig. 4D).
Effects of BCL2L11 silencing in SGC7901
To give a better understanding of BCL2L11-involved path-
way in gastric cancer cells, siRNA was used to knock-down
BCL2L11 in SGC7901 cells. Transfection of BCL2L11 siRNA
leads to a sharp decrease in protein expression (Fig. 5A and
5B), thus signiﬁcantly suppressing cell apoptosis and pro-
moting cell proliferation (Fig. 5C–E). Therefore, BCL2L11
acts as a cancer suppresser in GC; its dramatic down-reg-
ulation contributes to the reduced cell death and fast cell
growth rate in cancer.
The miR-24-BCL2L11 pathway regulates tumor growth
in vivo
Subsequently, we assessed the effects of miR-24 or
BCL2L11 in tumor growth by using mouse implanted tumor
model. SGC7901 cells were transfected with lentivirus par-
ticles to overexpress miR-24 or BCL2L11 respectively, and
cells were injected subcutaneously in the armpit of nude
mice. As is shown in Fig. 6A and 6B, overexpression of miR-
24 increases tumor size and weight obviously; while the
overexpression of BCL2L11 strongly inhibits tumor growth.
The levels of miR-24 and BCL2L11 were also detected in the
excised tumors. It is showed that miR-24 was elevated
ﬁvefold in miR-24-overexpression group, and BCL2L11
increased nearly 3 folds in BCL2L11-overexpression group





































































































































Figure 2. MiR-24 regulates BCL2L11 expression in gastric cancer cells. (A) Quantitative RT-PCR analysis of miR-24 levels in
SGC7901 cells transfected with mimics or inhibitors. (B and C) Direct recognition of BCL2L11 by miR-24. HEK293T cells were co-
transfected with ﬁreﬂy luciferase reporters containing either WT or mutant BCL2L11 3′UTR with miR-24 mimics and inhibitors. The
interaction between miR-24 and target 1 (B) or target 2 (C) was shown respectively. (D) The suppression of BCL2L11 expression by
miR-24 in SGC7901 cells. (E) Quantitative analysis of (D). (F) Quantitative RT-PCR analysis of BCL2L11 mRNA expression in
SGC7901 cells. ** indicates P < 0.01; * indicates P < 0.05.
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Figure 3. Onco-miR-24 regulates proliferation, apoptosis and migration of GC cells. SGC7901 cells were transfected with
miR-24 mimics or inhibitors, and cell growth, apoptosis and migration were evaluated respectively. (A) Overexpression of
miR-24 promotes cell proliferation of SGC7901 cells. (B) Knockdown of miR-24 suppress GC cell growth. (C) MiR-24 inhibits cell
apoptosis of SGC7901 cells. (D) Quantitative analysis of (C). (E and F) Transwell assays show that miR-24 promotes cell migration of
GC cells. (G) Validation of miR-24-mediated cell migration by scraping line method. ** indicates P < 0.01.
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in vivo experiments further demonstrated that the miR-24
acts as an onco-miRNA by inhibiting BCL2L11 expression in
gastric cancer.
DISCUSSION
Given the current incomplete knowledge of the pathways
comprising of miRNAs and the down-stream target proteins
in cancer, more studies are needed to be focused on these
dys-regulated miRNAs. MiRNA proﬁles are believed to pro-
vide an accurate diagnosis for different types of cancer,
contributing to the disorder of protein expression in cancer
cells. Although miR-24 has been found to be up-regulated in
both GC tissues and cell lines (Volinia et al., 2006; Tcher-
nitsa et al., 2010; Tsukamoto et al., 2010), its function in the
process of tumorigenesis remains unclear. Moreover, the
expression pattern and function of BCL2L11 in cancer,
especially in GC, have not been explored yet.
In this study, miR-24 and BCL2L11 levels showed oppo-
site trends in 6 pairs of gastric carcinoma and para-carci-
noma tissues. The obvious inhibition of BCL2L11 is surely to
contribute to decreased apoptosis and accelerated prolifer-
ation of cancer cells, and is resulted from the high expres-
sion of miR-24. The subsequent experiments suggest that
the miR-24-BCL2L11 pathway is involved in the processes of
cell growth, migration and apoptosis, thus regulating
tumorigenesis. We have previously reported the serum
miRNA proﬁle in GC, and found that miR-24 is down-regu-
lated in the serum of GC patients (Liu et al., 2011). We
believed that the secretion of onco-miR-24 from gastric
cancer cells is reduced, resulting in the up-regulation of miR-
24 in cancer cells and the down-regulation in serum. How-
ever, this needs more evidence in further studies.
For decades, chemotherapy and radiation are the main
therapeutic methods for cancer, causing cell killing without
speciﬁc targeting (Amit et al., 2011; McBride et al., 2013;
Manyam et al., 2015). A better comprehension of cancer,
especially the molecular mechanism that regulates tumor
growth, provides novel drug targets for future clinical use.
MiRNAs are proved to be a useful biomarker in the diagnosis
and prognosis of cancer, new diagnostic kit based on serum
miRNA proﬁle have been developed for consumer marketing
(Lin et al., 2015). Our group had reported that miRNAs and
other small RNAs trafﬁcked by MVs or plasmids can be used
for the treatment of diseases, including cancer, in mouse
models (Liu et al., 2013; Yin et al., 2014; Zhang et al., 2014).
Therefore, miRNAs have a good prospect in clinical
application.
To conclude, we illustrated that an important cell-apop-









































































Figure 4. BCL2L11 rescues miR-24-induced cell growth and migration. SGC7901 cells were co-transfected with miR-24 mimics
and BCL2L11 lenti-virus plasmid. The protein levels were detected by Western blot, and cell growth and migration were determined
by CCK8 and Transwell assays respectively. (A) Western blot analysis of BCL2L11 expression in SGC7901 cells co-overexpressed
with miR-24 and BCL2L11. (B) Quantitative analysis of (A). (C and D). Cell proliferation (C) and migration (D) of SGC7901 cells
treated with miR-24 mimics and BCL2L11 lenti-virus simultaneously. ** indicates P < 0.01.
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cancer. This novel pathway provides potential targets by
using miRNAs for gene therapy.
MATERIALS AND METHODS
Animals
Male nude mice (BALB/c-nu, 6∼8 weeks) were purchased and were
housed in a pathogen-free animal facility with access to water and
food and allowed to eat and drink ad libitum. All of the experimental
procedures were performed in accordance with protocols approved
by the Institutional Animal Care and Research Advisory Committee
of Tianjin Medical University.
Human tissue
Human gastric cancer tissues and paired adjacent noncancerous
tissues were derived from patients undergoing a surgical procedure
at the Tianjin Medical University Cancer Institute and Hospital
(Tianjin, China). Both tumor tissues and noncancerous tissues were
conﬁrmed histologically. The pathological type of each cancer was
determined to be adenocarcinoma. Written consents were provided
by all of the patients, and the Ethics Committee of Tianjin Medical
University Cancer Institute and Hospital approved all aspects of this
study. Tissue fragments were immediately frozen in liquid nitrogen at
the time of surgery and stored at −80°C.
Cell culture
Human gastric cell line SGC7901, human embryo kidney epithelial
cell line HEK293T were cultured in DMEM (Gibco, USA), which was
supplemented with 10% fetal bovine serum (FBS, Gibco, USA) in a
humidiﬁed incubator at 37°C with 5% CO2.
RNA isolation and quantitative RT-PCR
Assays to quantify mature miRNAs were conducted as previously
described with slight modiﬁcations (Chen et al., 2005; Andrews
GAPDH
BCL2L11























































































Figure 5. Knock-down of BCL2L11 in SGC7901 cells. (A and B) Silencing of BCL2L11 expression by siRNA. SGC7901 cells were
transfected with BCL2L11 siRNA, and the protein levels (A) and mRNA levels (B) were detected respectively. (C) Knock-down of
BCL2L11 strongly enhances cell growth in GC cells. (D and E) Silencing of BCL2L11 clearly reduces cell apoptosis of SGC7901 cells.
** indicates P < 0.01; *** indicated P < 0.001.
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et al., 2015). Total RNA was extracted from the cultured cells and
tissues using TRIzol Reagent (Invitrogen) according to the manu-
facturer’s instructions. miRNA determination was performed using
Taqman microRNA probes (Applied Biosystems, Foster City, CA). All
of the reactions were run in triplicate. After the reactions were
completed, the cycle threshold (CT) data were determined using
ﬁxed threshold settings, and the mean CT was determined from
triplicate PCRs. A comparative CT method was used to compare
each condition to the control reactions. U6 snRNA was used as an
internal control of miRNAs, and the mRNA levels of BCL2L11 was
normalized to GAPDH. The relative amount of gene normalized to
control was calculated with the equation 2−ΔCT, in which ΔCT =
CT gene − CT control. Primers of BCL2L11 and GAPDH were as
follows: 5′-AGAAGGCTGGGGCTCATTTG-3′ (GAPDH, sense);
5′-AGGGGCCATCCACAGTCTTC-3′ (GAPDH, antisense); 5′-CACC
AGCACCATAGAAGAA-3′ (BCL2L11, sense); 5′-ATAAGGAGC
AGGCACAGA-3′ (BCL2L11, antisense).
Cell transfection
SGC 7901 Cells were seeded in a 6-well plate and transfection was
conducted after 24 h. The BCL2L11 overexpressing lentivirus and
the control lentivirus were bought from GenePharma (Shanghai,
China),and 106 lentivirus were added into every single well with
gentle mixing. Cell transfection with miR-24 mimics and inhibitors
were conducted by using Lipofectamine 2000 (Invitrogen) according
to the manufacturer’s instructions. For each well, equal doses (100
pmol) of miRNA mimics, inhibitors, siRNAs (Santa Cruz, sc-29802),
or scrambled negative control RNA were used. The cells were har-
vested at 24 h after transfection for real-time quantitative PCR
analysis and western blotting.
Luciferase assay
Part of the wild type and mutated 3′UTR of BCL2L11, containing the

































































































Figure 6. MiR-24 promotes tumorigenesis by suppressing BCL2L11 expression in vivo. (A) Representative image of tumors
excised from nude mice. SGC7901 cells were treated with miR-24-overexpressing lenti-virus, BCL2L11-overexpressing lenti-virus
and the control lenti-virus respectively, and cells were implanted in BALB/c mice. (B) Weight of tumors from mice implanted with
SGC7901 cells. (C) Quantitative RT-PCR analysis of miR-24 in implanted tumors. (D–F) BCL2L11 expression in implanted tumors.
Western blot analysis of BCL2L11 levels (D); quantitative analysis of (E); Relative levels of BCL2L11 mRNA in implanted tumors (F).
** indicates P < 0.01.
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into a p-MIR-report plasmid (Genescript, Nanjing, China). For luci-
ferase reporter assays, 2 mg of ﬁreﬂy luciferase reporter plasmid,
2 mg of β-galactosidase expression vector (Ambion), and equal
amounts (200 pmol) of mimics, inhibitors, or scrambled negative
control RNA were transfected into cells. And the β-galactosidase
vector was used as a transfection control. At 24 h after transfection,
cells were assayed using luciferase assay kit (Promega).
Cell ﬂow assays
For cell cycle analysis, cells were washed with phosphate-buffered
saline solution (PBS) and ﬁxed in 70% ethanol at 4°C for 2–4 h. After
ﬁxation, cells were washed twice with PBS before re-suspension in
propidium iodide/RNase A solution (5 μg/mL propidium iodide and
100 mg/mL RNase A). Cells were incubated with propidium iodide at
room temperature in the dark for 1 h, then the stained cells were
analyzed by ﬂow cytometry.
For cell apoptosis analysis, cells were cultured overnight with
both serum-containing complete medium and serum-depleted
medium; the attached cells and ﬂoating cells were then harvested.
Flow cytometry analysis of apoptotic cells was carried out using an
Annexin V-FITC/PI staining kit (BD Biosciences, CA, USA). After
washes with cold PBS, the cells were re-suspended in binding buffer
(100 mmol/L HEPES, pH 7.4, 100 mmol/L NaCl, and 25 mmol/L
CaCl2) followed by staining with Annexin V-FITC/PI at room tem-
perature in darkness for 15 min. Apoptotic cells were then evaluated
by gating PI and Annexin V-positive cells on a ﬂuorescence-acti-
vated cell-sorting (FACS) ﬂow cytometer (BD Biosciences, San
Jose, CA). All experiments were performed in triplicate.
Cell proliferation assay
SGC7901 cells were collected at 12 h, 24 h, 36 h and 48 h post-
transfection; 10 μL of WST-8 was added into a corresponding test
well and incubated for 4 h. Absorbance was measured at a wave-
length of 490 nm.
Cell migration assay
Migration assayswere performed using either scrapping linemethod or
6.5 mm Transwell® with 8.0 μm Pore Polycarbonate Membrane Insert
(Corning, NewYork, USA) according to themanufacturer’s instructions.
At 24 h post-transfection with miR-24 mimics, inhibitors and controls,
SGC-7901 cells were incubated in for 24 h, and then 1 × 105 cells in
200μLserum-freemediumwereadded to theupper chamber.Avolume
of 500 μL of 10% FBS-containing mediumwas then added to the lower
chamber as a chemo-attractant. Cells were incubated for another 24 h
at 37°C, and then non-migrating cells on the upper surface of the
membrane were gently scraped off with cotton swabs. Cells that
migrated to the bottom of themembranewere stainedwith the cell stain
provided in the assay kit for 20min and visualized under a microscope.
To minimize the bias, at least three randomly selected ﬁelds with 200×
magniﬁcation were counted, and the average number was taken.
Establishment of tumor xenograft in nude mice
SGC7901 cells treated with control lentivirus or miR-24 overex-
pressing lentivirus or BCL2L11 overexpressing lentivirus were
injected subcutaneously into nude mice (1 × 107 cells for one
mouse). Mice were sacriﬁced after 4 weeks, and the weight and
diameter of tumors were recorded.
The miRNA target prediction
The miRNA target prediction and analysis were performed with the
algorithms from TargetScan (http://www.targetscan.org/) PicTar (http://
pictar.mdc-berlin.de/) and miRanda (http://www.microrna.org/).
Western blotting analysis
The BCL2L11 expression was assessed by Western blotting analysis
and samples were normalized to GAPDH. Protein extraction was
blocked with PBS-5% fat-free dried milk at room temperature for 1 h
and incubated at 4°C overnight with anti-BCL2L11 (1:500, Santa
Cruz), and anti-GAPDH (1:2000, Santa Cruz) antibodies respectively.
Statistical analyses
All data were representative of at least three independent experi-
ments. Data were expressed as mean ± S.E.M of at least three
separate experiments. Statistical signiﬁcance was considered at
P < 0.05 using the Student’s t-test. In this study, ‘*’ indicates
‘P < 0.05’, ‘**’ indicates ‘P < 0.01’, and ‘***’ indicates ‘P < 0.001’.
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